{"id":294,"date":"2022-03-21T15:34:03","date_gmt":"2022-03-21T15:34:03","guid":{"rendered":"https:\/\/amm-journal.org\/?p=294"},"modified":"2022-03-21T15:34:03","modified_gmt":"2022-03-21T15:34:03","slug":"regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies","status":"publish","type":"post","link":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/","title":{"rendered":"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies"},"content":{"rendered":"

Announcing a new review article publication for Acta Materia Medica<\/em> journal. Coronavirus disease 2019, responsible for a global pandemic, is caused by the severe acute respiratory syndrome coronavirus 2. Several vaccines have been developed and approved worldwide, particularly in China. As of Oct 17, 2021, four new coronavirus vaccines in China have been conditionally approved for marketing by the National Medical Products Administration, two of which have been authorized for emergency use in the Emergency Use Listing of the World Health Organization. Domestic vaccine R&D in China has relied on legal and regulatory support.<\/p>\n

This article summarizes the regulatory policy for vaccine development, review and approval. Vaccine approval laws have been continually improved, and regulations for special approval have been used to shorten the review time. China has coordinated pandemic-related needs, both domestically and with other countries, and made substantial progress in cooperative international anti-pandemic efforts.<\/p>\n

Article Reference:<\/strong> Jingshu Yang and Yue Yang. Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies.\u00a0Acta Materia Medica.\u00a0<\/em>Vol. 1(1):96-105. DOI: 10.15212\/AMM-2021-0008<\/a><\/p>\n

Keywords:<\/strong> COVID-19 vaccines, R&D, regulatory science, approval<\/p>\n

Acta Materia Medica<\/em> welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.<\/p>\n

Submission Process<\/strong><\/p>\n

Submissions to Acta Materia Medica<\/em> are made using ScholarOne, the online submission and peer review system. Registration and access are available at https:\/\/mc04.manuscriptcentral.com\/ammed<\/a><\/p>\n

Queries about the journal can be sent to editorialoffice@amm-journal.org.<\/p>\n

Please visit https:\/\/amm-journal.org\/<\/a> to learn more about the journal.<\/p>\n

Editorial Board:<\/strong> https:\/\/amm-journal.org\/index.php\/editorial-board\/<\/a><\/p>\n

There are no author submission or article processing fees.<\/p>\n

Follow Acta Materia Medica <\/em><\/strong>on Twitter https:\/\/twitter.com\/AMM_journal<\/a>\u00a0 ; Facebook<\/a> (https:\/\/www.facebook.com\/AMMjournal<\/a>)<\/p>\n

eISSN <\/strong>2737-7946<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Announcing a new review article publication for Acta Materia Medica journal. Coronavirus disease 2019, responsible for a global pandemic, is caused by the severe acute respiratory syndrome coronavirus 2. Several vaccines have been developed and approved worldwide, particularly in China. As of Oct 17, 2021, four new coronavirus vaccines in China have been conditionally approved […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-294","post","type-post","status-publish","format-standard","hentry","category-news-and-events"],"yoast_head":"\nRegulatory lessons from China\u2019s COVID-19 vaccines development and approval policies - AMM Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies - AMM Journal\" \/>\n<meta property=\"og:description\" content=\"Announcing a new review article publication for Acta Materia Medica journal. Coronavirus disease 2019, responsible for a global pandemic, is caused by the severe acute respiratory syndrome coronavirus 2. Several vaccines have been developed and approved worldwide, particularly in China. As of Oct 17, 2021, four new coronavirus vaccines in China have been conditionally approved […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/\" \/>\n<meta property=\"og:site_name\" content=\"AMM Journal\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-21T15:34:03+00:00\" \/>\n<meta name=\"author\" content=\"Compuscript\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Compuscript\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/\"},\"author\":{\"name\":\"Compuscript\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#\\\/schema\\\/person\\\/0935dba5c919585e39f756ce09930a67\"},\"headline\":\"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies\",\"datePublished\":\"2022-03-21T15:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/\"},\"wordCount\":302,\"commentCount\":0,\"articleSection\":[\"News and Events\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/\",\"url\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/\",\"name\":\"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies - AMM Journal\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#website\"},\"datePublished\":\"2022-03-21T15:34:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#\\\/schema\\\/person\\\/0935dba5c919585e39f756ce09930a67\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/03\\\/21\\\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/amm-journal.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#website\",\"url\":\"https:\\\/\\\/amm-journal.org\\\/\",\"name\":\"AMM Journal\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/amm-journal.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#\\\/schema\\\/person\\\/0935dba5c919585e39f756ce09930a67\",\"name\":\"Compuscript\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g\",\"caption\":\"Compuscript\"},\"sameAs\":[\"https:\\\/\\\/amm-journal.org\"],\"url\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/author\\\/ammjadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies - AMM Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/","og_locale":"en_GB","og_type":"article","og_title":"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies - AMM Journal","og_description":"Announcing a new review article publication for Acta Materia Medica journal. Coronavirus disease 2019, responsible for a global pandemic, is caused by the severe acute respiratory syndrome coronavirus 2. Several vaccines have been developed and approved worldwide, particularly in China. As of Oct 17, 2021, four new coronavirus vaccines in China have been conditionally approved […]","og_url":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/","og_site_name":"AMM Journal","article_published_time":"2022-03-21T15:34:03+00:00","author":"Compuscript","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Compuscript","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/#article","isPartOf":{"@id":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/"},"author":{"name":"Compuscript","@id":"https:\/\/amm-journal.org\/#\/schema\/person\/0935dba5c919585e39f756ce09930a67"},"headline":"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies","datePublished":"2022-03-21T15:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/"},"wordCount":302,"commentCount":0,"articleSection":["News and Events"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/","url":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/","name":"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies - AMM Journal","isPartOf":{"@id":"https:\/\/amm-journal.org\/#website"},"datePublished":"2022-03-21T15:34:03+00:00","author":{"@id":"https:\/\/amm-journal.org\/#\/schema\/person\/0935dba5c919585e39f756ce09930a67"},"breadcrumb":{"@id":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/amm-journal.org\/index.php\/2022\/03\/21\/regulatory-lessons-from-chinas-covid-19-vaccines-development-and-approval-policies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/amm-journal.org\/"},{"@type":"ListItem","position":2,"name":"Regulatory lessons from China\u2019s COVID-19 vaccines development and approval policies"}]},{"@type":"WebSite","@id":"https:\/\/amm-journal.org\/#website","url":"https:\/\/amm-journal.org\/","name":"AMM Journal","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/amm-journal.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/amm-journal.org\/#\/schema\/person\/0935dba5c919585e39f756ce09930a67","name":"Compuscript","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g","caption":"Compuscript"},"sameAs":["https:\/\/amm-journal.org"],"url":"https:\/\/amm-journal.org\/index.php\/author\/ammjadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts\/294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/comments?post=294"}],"version-history":[{"count":1,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts\/294\/revisions"}],"predecessor-version":[{"id":295,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts\/294\/revisions\/295"}],"wp:attachment":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/media?parent=294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/categories?post=294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/tags?post=294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}